Fragile histidine triad (FHIT) and p53 gene inactivaton as response markers in non-small-cell lung cancer (NSCLC) patients treated with platinum-analogue regimen: Retrospective analysis

被引：0
|
作者：
Cortinovis, Diego
Bajetta, Emilio
Sozzi, Gabriella
Mariani, Luigi
Fabbri, Alessandra
Livio, Anna
Roz, Luca
Formisano, Barbara
Zilembo, Nicoletta
Bidoli, Paolo
机构：
[1] Ist Nazl Studio & Cura Tumori, Med Oncol Unit 2, I-20133 Milan, Italy
[2] Ist Nazl Studio & Cura Tumori, Dept Expt Oncol, I-20133 Milan, Italy
[3] Ist Nazl Studio & Cura Tumori, Stat Med Dept, I-20133 Milan, Italy
[4] Ist Nazl Studio & Cura Tumori, Anat Pathol Unit, I-20133 Milan, Italy
来源：
ANNALS OF ONCOLOGY | 2006年 / 17卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：253 / 253
页数：1
相关论文
共 50 条
  • [21] MERIT: Analysis of differential gene expression in patients (pts) with advanced non-small-cell lung cancer (NSCLC) treated with erlotinib
    Delmar, P.
    Tan, E. H.
    Pluzanska, A. G.
    Ramlau, R.
    Reck, M.
    McLoughlin, P.
    Baselga, J.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [22] Adenovirus-mediated p53 gene transfer in sequence with cisplatin to tumors of patients with non-small-cell lung cancer
    Nemunaitis, J
    Swisher, SG
    Timmons, T
    Connors, D
    Mack, M
    Doerksen, L
    Weill, D
    Wait, J
    Lawrence, DD
    Kemp, BL
    Fossella, F
    Glisson, BS
    Hong, WK
    Khuri, FR
    Kurie, JM
    Lee, JJ
    Lee, JS
    Nguyen, DM
    Nesbitt, JC
    Perez-Soler, R
    Pisters, KMW
    Putnam, JB
    Richli, WR
    Shin, DM
    Walsh, GL
    Merritt, J
    Roth, J
    JOURNAL OF CLINICAL ONCOLOGY, 2000, 18 (03) : 609 - 622
  • [23] P53 codon 72 polymorphism increases the risk of somatic P53 gene mutations in non-small cell lung cancer (NSCLC)
    Szymanowska, A
    Jassem, E
    Dziadziuszko, R
    Borg, A
    Limon, J
    Kobierska-Gulida, G
    Skokowski, J
    Jassem, J
    LUNG CANCER, 2005, 49 : S75 - S75
  • [24] Relation between P53 codon 72 polymorphism and somatic P53 gene mutation in non-small cell lung cancer (NSCLC)
    Jassem, J.
    Szymanowska, A.
    Jassem, E.
    Dziadziuszko, R.
    Borg, A.
    Limon, J.
    Kobierska-Gulida, G.
    Skokowski, J.
    EJC SUPPLEMENTS, 2005, 3 (02): : 336 - 336
  • [25] p53 nuclear immunostaining and gene mutations in non-small-cell lung cancer and their effects on patient survival
    Mitsudomi, T
    Oyama, T
    Nishida, K
    Ogami, A
    Osaki, T
    Nakanishi, R
    Sugio, K
    Yasumoto, K
    Sugimachi, K
    ANNALS OF ONCOLOGY, 1995, 6 : 9 - 13
  • [26] Cyclin D1 overexpression in correlation with pRb and p53 status in non-small-cell lung cancer (NSCLC)
    Dworakowska, D
    Jassem, E
    Jassem, J
    Boltze, C
    Wiedorn, KH
    Karmolinski, A
    Dworakowski, R
    Lapinski, M
    Tomaszewski, D
    Skokowski, J
    Jaskiewicz, K
    Czestochowska, E
    LUNG CANCER, 2004, 45 : S31 - S31
  • [27] P53, FHIT, K-RAS GENE MUTATIONS ARE ASSOCIATED WITH SMOKING IN NON-SMALL CELL LUNG CANCER BY META-ANALYSIS
    Ma, L.
    Zhao, M-J
    Wang, Q. L. Xiu-Lin
    Wang, X-G
    RESPIROLOGY, 2011, 16 : 133 - 136
  • [28] A cost utility analysis of erlotinib in patients with previously treated advanced non-small-cell lung cancer (NSCLC)
    Bradbury, P. A.
    Jang, R.
    Isogai, P.
    Mittmann, N.
    Evans, W.
    Shepherd, F. A.
    Leighl, N. B.
    Ng, R.
    VALUE IN HEALTH, 2008, 11 (03) : A72 - A72
  • [29] P21WAF1/CIP1 and p53 protein expression in non-small-cell lung cancer (NSCLC)
    Dworakowska, D
    Jassem, E
    Jassem, J
    Boltze, C
    Wiedorn, KH
    Karmolinski, A
    Dworakowski, R
    Lapinski, M
    Tomaszewski, D
    Skokowski, J
    Jaskiewicz, K
    Czestochowska, E
    LUNG CANCER, 2004, 45 : S31 - S31
  • [30] COMPARATIVE-ANALYSIS OF P53 GENE-MUTATIONS AND PROTEIN ACCUMULATION IN HUMAN NON-SMALL-CELL LUNG-CANCER
    TOP, B
    MOOI, WJ
    KLAVER, SG
    BOERRIGTER, L
    WISMAN, P
    ELBERS, HRJ
    VISSER, S
    RODENHUIS, S
    INTERNATIONAL JOURNAL OF CANCER, 1995, 64 (02) : 83 - 91
12345